SPRINGFIELD, MA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)PIONEER VALLEY LIFE SCIENCES INSTITUTE OF BAYSTATE MEDICAL & UMASS AMHERSTINC, founded in 2004, is a micro nonprofit in the Medical Research sector that reported $82K in total revenue in fiscal year 2023. Expenses of $227K exceeded revenue, resulting in a 176% operating deficit.
TO IMPROVE HUMAN HEALTH BY DEVELOPING CREATIVE NEW APPROACHES FOR THE DIAGNOSIS AND TREATMENT OF DISEASE.
BREAST REGISTRYDESCRIPTION: ANALYSIS-READY DATASETS WITH PATIENT CHARACTERISTICS TOGETHER WITH TREATMENTS AND OUTCOMES ARE ESSENTIAL TO IDENTIFY SUCCESSES IN CLINICAL MANAGEMENT AND AREAS WHERE...
BREAST REGISTRYDESCRIPTION: ANALYSIS-READY DATASETS WITH PATIENT CHARACTERISTICS TOGETHER WITH TREATMENTS AND OUTCOMES ARE ESSENTIAL TO IDENTIFY SUCCESSES IN CLINICAL MANAGEMENT AND AREAS WHERE LIMITATIONS EXIST. WE HAVE CREATED A PROSPECTIVE REGISTRY FOCUSED ON BREAST CANCER. THIS RESOURCE INCLUDES A DETAILED SURVEY OF LIFESTYLE, HEALTH HISTORY ALONG WITH DIAGNOSTIC AND TREATMENT INFORMATION. TISSUE SPECIMENS ARE ALSO AVAILABLE FOR ALL THE PARTICIPANTS. THE REGISTRY PROVIDES ACCESS TO PATIENT DATA IN A PROSPECTIVE FASHION TO FACILITATE EVALUATIONS OF CLINICAL OUTCOMES.ACCOMPLISHMENTS: PRESENT ENROLLMENT TOTAL IS 1,600 PARTICIPANTS.
BREAST CELL REPOSITORY DESCRIPTION: NORMAL CELLS FROM A DIVERSE COHORT OF PATIENTS IS NEEDED TO IDENTIFY THE CELLULAR MECHANISMS RESPONSIBLE FOR THE WIDE VARIATION IN RESPONSES TO THERAPIES AMONG...
BREAST CELL REPOSITORY DESCRIPTION: NORMAL CELLS FROM A DIVERSE COHORT OF PATIENTS IS NEEDED TO IDENTIFY THE CELLULAR MECHANISMS RESPONSIBLE FOR THE WIDE VARIATION IN RESPONSES TO THERAPIES AMONG INDIVIDUALS. THIS EFFORT FOCUSES ON CREATION OF NORMAL BREAST EPITHELIAL CELLS THAT REFLECT THE VARIATION IN THE POPULATION OF WOMEN. METHODS ARE USED TO EXPAND THE CELLS IN VITRO PROVIDING A VERSATILE SOURCE FOR TESTING DIFFERENCES IN SENSITIVITY TO ENVIRONMENTAL CONTAMINANTS AND THERAPEUTIC COMPOUNDS. ACCOMPLISHMENTS: BREAST CELLS FROM 500 INDIVIDUALS AND GROWING. PROCEDURES TO IMMORTALIZE NORMAL BREAST CELLS FROM MOST PATIENTS HAVE BEEN ESTABLISHED. WE HAVE ESTABLISHED IMMORTALIZED CELL LINES FROM NORMAL BREAST EPITHELIUM FROM 17 DONORS REPRESENTING DIVERSE BREAST CANCER RISK. THE CELL LINES ARE GENETICALLY STABLE AND UNIQUE BASED ON GENETIC FINGERPRINTING. THESE ARE BEING USED TO DETERMINE DIFFERENCES IN SUSCEPTIBILITY TO ONCOGENIC TRANSFORMATION CAUSED BY CHEMICALS AND ALTERED CELL SIGNALING.
BIOSPECIMEN RESOURCES & MOLECULAR ANALYSIS FACILITYDESCRIPTION: THE FACILITY MAINTAINS THE EQUIPMENT AND PERSONNEL TO PROVIDE HISTOLOGICAL SERVICES. THIS GROUP ALSO ASSISTS INVESTIGATORS WITH...
BIOSPECIMEN RESOURCES & MOLECULAR ANALYSIS FACILITYDESCRIPTION: THE FACILITY MAINTAINS THE EQUIPMENT AND PERSONNEL TO PROVIDE HISTOLOGICAL SERVICES. THIS GROUP ALSO ASSISTS INVESTIGATORS WITH MAINTAINING IRB APPROVALS FOR TISSUE PROCUREMENT. ACCOMPLISHMENTS: SUPPORT SERVICES (HISTOLOGY, MOLECULAR ANALYSES) HAS BEEN USED BY INVESTIGATORS FROM UMASS AMHERST, UMASS MEDICAL SCHOOL, BAYSTATE HEALTH SYSTEMS AS WELL AS SERVING OTHER ACADEMIC SCIENTISTS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $82,298 | $81,262 | +0.0% |
| Expenses | $226,896 | $227,665 | 0.0% |
| Net Income | $-144,598 | $-146,403 | 0.0% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| PETER REINHART PHD | CHAIR | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| PETER FRIEDMANN | VICE CHAIR | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| PATRICK SHEEHY | DIRECTOR; TREASURER (END 6/2024) | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| ANDREW MANGELS | DIRECTOR (END 7/2024) | 5.00 |
Director
|
$0 | $0 | $0 |
| KEITH PARENT | DIRECTOR | 5.00 |
Director
|
$0 | $0 | $0 |
| JAY STEINGRUB | DIRECTOR | 5.00 |
Director
|
$0 | $0 | $0 |
| LAURA VANDENBERG | DIRECTOR | 5.00 |
Director
|
$0 | $0 | $0 |
| D JOSEPH JERRY | DIRECTOR; EX-OFFICIO (END 8/2024) | 5.00 |
Director
|
$0 | $0 | $0 |
| ASHRAF KHAN MD | DIRECTOR (START 7/2024) | 5.00 |
Director
|
$0 | $0 | $0 |
| TASHANNA MYERS MD | DIRECTOR (START 7/2024) | 5.00 |
Director
|
$0 | $0 | $0 |
| RAYMOND MCCARTHY | CFO | 5.00 |
Officer
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $82,298 | $226,896 | $756,115 | $-144,598 |
| 2023 | $81,262 | $227,665 | $867,391 | $-146,403 |
| 2022 | $78,598 | $241,703 | $982,741 | $-163,105 |
| 2021 | $145,961 | $254,386 | $1,115,623 | $-108,425 |
| 2020 | $5 | $255,041 | $1,227,576 | $-255,036 |
| 2019 | $5 | $260,175 | $1,416,172 | $-260,170 |
| 2018 | $77,468 | $264,620 | $1,606,937 | $-187,152 |
Compare PIONEER VALLEY LIFE SCIENCES INSTITUTE OF BAYSTATE MEDICAL & UMASS AMHERSTINC with other nonprofits in Massachusetts and across the country.